UMN Pharma
UMN Pharma is dedicated to developing a new generation of gentle vaccines using cutting-edge biotechnologies, aiming to make vaccines safe for babies, pregnant women, and the elderly. Their mission is to deliver these gentle vaccines quickly and to as many people as possible.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Recombinant protein vaccine candidates (in development)
Next-generation vaccine candidates developed with biotechnology methods and formulated for safety across infants, pregnant women, and elderly populations.
Recombinant protein vaccine candidates (in development)
Next-generation vaccine candidates developed with biotechnology methods and formulated for safety across infants, pregnant women, and elderly populations.
Services
On-site services covering initial process development for recombinant protein vaccines, manufacture of clinical trial materials, and scale-up to commercial production.
On-site services covering initial process development for recombinant protein vaccines, manufacture of clinical trial materials, and scale-up to commercial production.
Expertise Areas
- Vaccine research and development
- Recombinant protein vaccine development
- CMC and process scale-up
- Clinical supply manufacturing
Key Technologies
- Recombinant protein expression and purification
- Vaccine platform technologies
- Process development and scale-up methodologies
- Clinical trial material manufacturing
News & Updates
UMNファーマ announces the transfer of its vaccine production business to Shionogi Pharma through absorption-type company split, effective April 1, 2025, to strengthen collaboration and streamline vaccine manufacturing processes.
Shionogi Group announces approval for domestic manufacturing and sales of the COVID-19 recombinant protein vaccine 'Kobgoes® intramuscular injection'.
UMN Pharma celebrates its 20th anniversary and expresses gratitude.
UMN Pharma participated in a regional corporate career guidance event.
UMN Pharma participated in a blood donation activity.
Shionogi Group announces the start of a Phase 3 additional immunization trial for the Omicron XBB.1.5 strain-specific COVID-19 vaccine S-268023.
UMNファーマ announces the transfer of its vaccine production business to Shionogi Pharma through absorption-type company split, effective April 1, 2025, to strengthen collaboration and streamline vaccine manufacturing processes.
Shionogi Group announces approval for domestic manufacturing and sales of the COVID-19 recombinant protein vaccine 'Kobgoes® intramuscular injection'.
UMN Pharma celebrates its 20th anniversary and expresses gratitude.
UMN Pharma participated in a regional corporate career guidance event.
UMN Pharma participated in a blood donation activity.
Shionogi Group announces the start of a Phase 3 additional immunization trial for the Omicron XBB.1.5 strain-specific COVID-19 vaccine S-268023.